Literature DB >> 9434131

Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages.

D Pozo1, M Delgado, C Martinez, R P Gomariz, J M Guerrero, J R Calvo.   

Abstract

The present work characterizes the mRNA expression of PACAP type I receptors in rat peritoneal macrophages but not in peritoneal lymphocytes by both retrotranscriptase and polymerase chain reaction (RT-PCR) and homologous Southern hybridization and the stimulation by PACAP27, PACAP38 and vasoactive intestinal peptide (VIP) of sn-1,2-diacylglycerol production in rat peritoneal macrophage membranes. The binding of [125I]PACAP27 was time and cell concentration dependent. Scatchard analysis of displacement of the bound tracer by unlabeled PACAP27 indicates the existence of two classes of binding sites. The dissociation constant (Kd) was 0.64 +/- 0.08 nM and the maximal binding capacity (Bmax) was 8.85 +/- 1.45 fmol/10(6) cells for the high affinity binding site. The low affinity binding site had a Kd of 0.10 +/- 0.06 microM with a Bmax of 300 +/- 21.9 fmol/10(6) cells. Scatchard analysis of VIP displacement data indicated the presence of two classes of binding sites with a Kd and Bmax different to those of PACAP27. These results suggest that PACAP binds to two binding sites, PACAP type I receptors and PACAP type II receptors. The PACAP27-stimulated diacylglycerol production was not affected by treatment with pertussis toxin. However, the presence of GTP partially inhibited this PACAP27 stimulation of 1,2-diacylglycerol in a dose dependent manner, although GTP alone stimulates diacylglycerol accumulation. In conclusion, for the first time we demonstrate by biochemical and molecular biology criteria the existence of PACAP type I receptors on rat peritoneal macrophages and the evidence for coupling with a pertussis toxin-insensitive G regulatory protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434131     DOI: 10.1016/s0167-4889(97)00104-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice.

Authors:  H D Lauenstein; D Quarcoo; L Plappert; C Schleh; M Nassimi; C Pilzner; S Rochlitzer; P Brabet; T Welte; H G Hoymann; N Krug; M Müller; E A Lerner; A Braun; D A Groneberg
Journal:  Clin Exp Allergy       Date:  2010-11-09       Impact factor: 5.018

2.  Expression of pituitary adenylate cyclase-activating polypeptide in the primary lymphoid organs of the duck Anas platyrhynchos.

Authors:  Caterina Squillacioti; Nicola Mirabella; Adriana De Luca; Giuseppe Paino
Journal:  J Anat       Date:  2006-07       Impact factor: 2.610

3.  Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.

Authors:  Carmen Martinez; Catalina Abad; Mario Delgado; Alicia Arranz; Maria G Juarranz; Nieves Rodriguez-Henche; Philippe Brabet; Javier Leceta; Rosa P Gomariz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

4.  Mechanisms involved in protection afforded by L-arginine in ibuprofen-induced gastric damage: role of nitric oxide and prostaglandins.

Authors:  Dolores Jiménez; M José Martin; David Pozo; Catalina Alarcón; José Esteban; Leo Bruseghini; Antonio Esteras; Virginia Motilva
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

5.  Differential regulatory role of pituitary adenylate cyclase-activating polypeptide in the serum-transfer arthritis model.

Authors:  Bálint Botz; Kata Bölcskei; László Kereskai; Miklós Kovács; Tamás Németh; Krisztián Szigeti; Ildikó Horváth; Domokos Máthé; Noémi Kovács; Hitoshi Hashimoto; Dóra Reglődi; János Szolcsányi; Erika Pintér; Attila Mócsai; Zsuzsanna Helyes
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

6.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Authors:  Catalina Abad; Bhavaani Jayaram; Laurine Becquet; Yuqi Wang; M Sue O'Dorisio; James A Waschek; Yossan-Var Tan
Journal:  J Neuroinflammation       Date:  2016-06-29       Impact factor: 8.322

7.  Immunomodulatory Effects of the Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide in Acute Toxoplasmosis.

Authors:  Caio Andreeta Figueiredo; Henning Peter Düsedau; Johannes Steffen; Nishith Gupta; Miklos Pal Dunay; Gabor K Toth; Dora Reglodi; Markus M Heimesaat; Ildiko Rita Dunay
Journal:  Front Cell Infect Microbiol       Date:  2019-05-28       Impact factor: 5.293

Review 8.  Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential.

Authors:  Daria Augustyniak; Judyta Nowak; Fionnuala T Lundy
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

Review 9.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.